Not sure I follow the logic. 10mg, 20mg, 30mg, 50mg and from one presentation also 40mg have been used already.
I doubt the same PDD trial expanded to AU will use 4 dose levels and distributed with the majority of the dose arms on the lower doses in Spain and only AU on the higher doses.
Are you suggesting that the 10mg and 20mg registered by the EMA site is a new formulation with higher bioavailability corresponding to 30mg and 50mg?